PKU brain study reveals how new treatment may boost thinking skills
NCT ID NCT05356377
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug Palynziq, which lowers phenylalanine levels in the blood, affects the brain and thinking abilities in adults with phenylketonuria (PKU). Six participants who were already taking Palynziq underwent brain scans and cognitive tests to measure changes in brain structure and function. The goal was to understand the neurological improvements linked to long-term reduction of phenylalanine levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
University of Missouri
Columbia, Missouri, 65211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene infusion rewrite the fate of PKU?
- Newborn screening study aims to catch rare diseases at birth
- PKU Drug's nutritional impact under the microscope
- PKU diet in childhood may shape adult IQ, study finds
- New PKU drink passes small taste and tolerance test
- New PKU formula shows promise in managing blood levels